Trial Search Results
Intranasal Bevacizumab for HHT-Related Epistaxis
This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.
Stanford is currently accepting patients for this trial.
- Drug: Bevacizumab
- Drug: Placebo (Saline)
1. The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT)
2. The patient is to undergo treatment with electrocautery in the operating room under
3. The patient is able to give informed consent
4. The patient is at least 18 years old
1. The patient has had prior treatment with systemic or nasal bevacizumab within the past
2. The patient has undergone electrocautery for epistaxis within the 6 months prior to
3. The patient is a minor
4. The patient is pregnant
5. The patient is incapable of understanding the consent process
6. The patient has a history of HIV or another known cause of immunosuppression, or is
actively taking immunosuppressive medications due to organ transplantation, rheumatoid
disease, or other medical conditions.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study